3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1
7
Phase 1/2
5
Phase 4
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
6
Lymphoma
3
Lymphoma, T-Cell, Cutaneous
2
Hematologic Diseases
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Primary Cutaneous Anaplastic Large Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Dendritic Cell Sarcoma, Interdigitating
1
Interventions
Doxorubicin
8
Vincristine
7
Prednisone
7
Cyclophosphamide
7
Rituximab
5
VAP-cyclo protocol
3
Radiotherapy
3
Methotrexate
3
Filgrastim
3
Cytarabine
3
liposomal amphotericin B
2
Vinblastine
2
Levofloxacin
2
Leucovorin
2
Hydrocortisone
2
Etoposide
2
Early Intervention, Educational
2
Drug Therapy
2
Dexamethasone
2
Darbepoetin alfa
2
liposomal doxorubicin
1
ferrous sulfate
1
ferric gluconate
1
belinostat
1
Sucrose
1
Steroids
1
Stem Cell Transplantation
1
Standard of Care
1
Specimen Handling
1
Psychiatric Rehabilitation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Large-Cell, Anaplastic
×
Brentuximab Vedotin
×
Clear all
NCT01777152
2021-11-30
ECHELON-2
Seagen Inc.
Phase 3
Completed
452 enrolled
16 charts
1 FDA